Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Recruiting now
Conditions studied: Chronic Kidney Disease
In brief
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
Key facts
- Study ID
- NCT00327860
- Run by
- Johns Hopkins Bloomberg School of Public Health
- People needed
- 1300
- Starts
- 2003-10-01
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2026-04-17
Who can join
Age: 1 and older, up to 22. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
- Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
- Willingness and ability to provide informed consent and assent
- For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
You may not qualify if…
- Solid organ (other than kidney), bone marrow or stem cell transplantation
- Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
- Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
- HIV infection with detectable viral load despite current antiretroviral therapy
- Current pregnancy or pregnancy within past twelve months
- Inability to complete major data collection procedures
- Not fluent in English or Spanish
- Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
- Existing moderate to severe congenital structural heart disease
- Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
- History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
- For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited
Where it is running
- Children's Mercy Kansas City — Kansas City, Missouri, United States (enrolling)
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.